ClinicalTrials.gg
RecruitingNCT06180174Updated Dec 28, 2023

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

A Phase 1 interventional study of MC-1-50 in B Cell Lymphoma and Non Hodgkin Lymphoma, sponsored by Chongqing Precision Biotech Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-28.

Sponsored by Chongqing Precision Biotech Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 283 studies in Lymphoma, B-Cell with a site in China — 125 open to participants now, 146 under way, 9 of them phase 3. Lymphoma, B-Cell · China.

Planned enrollment
153rd of 273
24 · median 30
Started
2023
with 26 others
Phase 1
124 of 283
57 open now
Primary completion
2025-12
later than 30 of 145 live
Registered
182nd of 283
by date
Lead sponsor
6 of 283
Chongqing Precision Biotech Co., Ltd

Among the 283 studies in Lymphoma, B-Cell with a site in China, this one is the 153rd largest by planned enrollment of the 273 interventional ones that give a count, is one of 27 that started in 2023, is one of 124 in phase 1, reaches primary completion later than 30 of the 145 other live ones, and was the 182nd registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

125 of the 283 studies in Lymphoma, B-Cell with a site in China are open now. Recruiting first, the newest first:

120 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Lymphoma, B-Cell with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, open-label, dose-escalation phase I clinical study to explore the safety, tolerability, and cytokinetic characteristics of MC-1-50 cell formulation, and to preliminarily observe the efficacy of MC-1-50 cell formulation in subjects with relapsed/refractory CD19-positive B-cell non-Hodgkin lymphoma.

Read the detailed description

Based on the specific CD19-targeting CAR-T developed on the PrimeCARTM platform, the cell preparation time is about 3 days, which can greatly shorten the waiting time of patients, improve production efficiency and reduce production costs. At the same time, MC-1-50 products have a high proportion of T naive cells, which can play a therapeutic effect at a very small infusion dose to improve safety. In this study, a "3+3" design was adopted, and four dose groups were set up with 1×105/kg, 3×105/kg, 5×105/kg, and 10×105/kg CAR-positive cells, respectively (the upper limit of the total number of cells was not more than 1×108 CAR-positive cells). All subjects received only one infusion of MC-1-50 cells.

03

Conditions studied

  • B Cell Lymphoma
  • Non Hodgkin Lymphoma

Keywords

  • CAR-T
  • CD19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient or his/her guardian agrees to participate in the clinical trial and signs the ICF, indicating that he/she understands the purpose and procedure of the clinical trial and is willing to participate in the study;
  2. Age ≥18 years old, gender unlimited;
  3. Confirmed cytological or histological diagnosis of B-cell non-Hodgkin lymphoma according to WHO 2017 criteria, including the following pathological types:

    1. Diffuse large B-cell lymphoma: including non-specific type (DLBCL, NOS), chronic inflammatory associated DLBCL, primary cutaneous DLBCL (leg type), EBV-positive DLBCL (NOS);
    2. High-grade B-cell lymphomas (including NOS and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements);
    3. Primary mediastinal large B-cell lymphoma;
    4. Rich T/ histiocytic large B-cell lymphoma;
    5. Transformed DLBCL (e.g., transformed DLBCL of follicular lymphoma, chronic lymphocytic leukemia/small B lymphocytic lymphoma, marginal zone lymphoma, etc.);
    6. Grade 3b follicular lymphoma (FL3b);
  4. Have received adequate treatment with CD20 monoclonal antibody and anthracyclines in the past (except for those who are negative for CD20 and anthracyclines, or who are unable to tolerate or adapt to CD20 monoclonal antibody therapy or have other conditions in which the use of CD20 monoclonal antibody is not considered appropriate by the investigators), For those who are allergic to CD20 monoclonal antibody, or have intolerable serious adverse reactions after use, or have active infections and serious cardiovascular problems, etc.), the definition of relapse or is met during screening:

    1. Recurrence: recurrence of disease progression or recurrence after achieving CR with standard treatment;
    2. Difficult to treat: The best curative effect after at least 4 courses of treatment/at least 2 courses of end-line treatment (2 lines and more) is disease stabilization (SD), and the SD maintenance time after the last dose is not more than 6 months; Or the best response to the last treatment was disease progression (PD);
    3. No remission, disease progression or recurrence after hematopoietic stem cell transplantation;
    4. Patients with transformational lymphoma who received chemotherapy prior to transformation and did not go into remission, disease progression, or relapse after salvage therapy after transformation.
  5. Immunohistochemical or flow cytometry results showed positive CD19 expression;
  6. 0 \~ 1 points;
  7. The expected survival time is 12 weeks or more;
  8. According to the 2014 edition of Lugano standard, there is at least one two-dimensional as the evaluation basis: for intranodular lesion, it is defined as: long diameter >1.5cm; For extranodal lesions, the length diameter should be >1.0cm;
  9. The functions of important organs are basically normal:

    1. Cardiac function: cardiac echocardiography suggests cardiac ≥50%;
    2. Serum creatinine ≤2.0× , or ≥60ml/min (CockcroftGault formula);
    3. and AST≤3.0×ULN (≤5.0×ULN for patients with liver invasion);
    4. Total ≤1.5 ×ULN (total bilirubin ≤3.0 ×ULN in Gilbert syndrome);
    5. Blood oxygen saturation ≥92% in non-oxygen state;
    6. Blood routine: neutrophils ≥1.0×109/L, ≥75×109/L, ≥80g/L (with bone marrow invasion, neutrophils ≥0.5×109/L, platelets ≥50×109/L).
  10. No serious mental disorders;
  11. The venous access required for collection can be established, and mononuclear cell collection can be performed according to the judgment of the researcher, and there are no for other cell collection;
  12. Women of childbearing age who have had a negative pregnancy test and all subjects agree to use a reliable and effective method for contraception (excluding safe period contraception) for 1 year from signing the to receiving the infusion of MC-1-50 cells. Including but not limited to: abstinence, can inhibit ovulation implantable progesterone contraceptive; Intrauterine device (IUD); Intrauterine hormone release system; Spousal vasectomy; Combined hormonal contraceptives (oral, vaginal, and transdermal) that inhibit ovulation; Progesterone contraceptives (oral or injectable) that inhibit ovulation; Male subjects who have sex with a fertile female must consent to the use of a barrier method of contraception (e.g., condom plus spermicidal foam/gel/film/emulsion/suppository). At the same time, the subject should promise not to donate eggs (egg cells, oocytes) or sperm for assisted reproduction within 1 year after the cell infusion.

Exclusion criteria

Exclusion Criteria:

  1. Secondary CNS lymphoma was allowed to be included, except those with active CNS invasion or symptoms of CNS involvement or primary CNS lymphoma at the time of screening;
  2. Patients who have received CAR-T therapy or other gene-modified cell therapy before screening;
  3. Received hematopoietic stem cell transplantation (allo-HSCT) before screening;
  4. Received the following anti-tumor therapy before cell infusion: received chemotherapy, targeted therapy and other drug treatment (preconditioning) within 14 days or at least 5 half-lives (whichever is longer)

    Except for therapy and sheath chemotherapy for CNS lymphoma, which should be stopped 1 week before cell infusion); Received radiation within 14 days;

  5. surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA detection greater than the normal range; virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA detection greater than the normal range; Positive for (HIV) antibodies; Syphilis positive; Cytomegalovirus (CMV) DNA test positive;
  6. Have any of the following heart conditions:

    1. (NYHA) Stage III or IV congestive heart failure;
    2. Had myocardial infarction or coronary artery bypass grafting (CABG) within 6 months prior to enrollment;
    3. A history of ventricular arrhythmia, or unexplained syncope (other than those caused by vasovagal or dehydration);
    4. History of severe non-ischemic cardiomyopathy;
  7. Active or uncontrollable infection requiring systemic treatment exists within 1 week prior to screening;
  8. Grade 2 to 4 acute (GVHD) or moderate to severe chronic GVHD were present within 4 weeks prior to screening;
  9. Cerebrovascular accident or seizure occurred within 6 months before screening;
  10. Occurrence of deep vein or deep artery embolization events within 6 months before screening;
  11. Poor control of hypertension at screening, defined as systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg (blood pressure values are measured based on the average of 3 readings taken at least 2 minutes apart

    Patients with blood pressure ≥160/100mmHg at the initial screening can receive antihypertensive treatment, and if the blood pressure is well controlled after treatment and the blood pressure \< 160/100mmHg can be screened);

  12. Known to have active or uncontrolled diseases, such as Crohns disease, rheumatoid arthritis, systemic lupus erythematosus, systemic vasculitis, etc., except skin diseases that do not require systemic treatment (e.g. Psoriasis);
  13. Screening for interstitial lung disease requiring treatment;
  14. Malignant tumors other than B-cell non-Hodgkin's lymphoma (except tumors with no active lesion and after treatment > 2 years, and adequately treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery);
  15. Received within 4 weeks prior to screening;
  16. Participated in other interventional clinical studies within 4 weeks or 5 half-lives prior to screening;
  17. Women who are pregnant or breastfeeding, as well as male or female subjects who plan to have a family within 1 year after receiving MC-1-50 cell transfusion;
  18. Circumstances deemed unsuitable for participation in the study by other researchers.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    MC-1-50 cell preparation

    Patients will be be treated with CD19 CAR- T cells

    Biological: MC-1-50

Interventions

  • BiologicalMC-1-50

    A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    The incidence of adverse events after CAR-T cell infusion was assessed by the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, version 5.0)

    Time frame: 1 month

  2. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Dose-limiting toxicity after CD19 CAR-T cell infusion

    Time frame: 1month

Secondary outcomes

  1. Assessing objective response rate(ORR) of CAR-T cell preparations in CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma[Effectiveness]

    Objective response rate after infusion 1 month and 3 month: The proportion of subjects who achieved CR, PR after CAR-T infusion accounted for all treated subjects (Assessed by investigators according to the Lugano 2014 criteria)#the minimum value is 0%#maximum value is 100%, and higher scores mean a better outcome.

    Time frame: 3 months

  2. Assessing best overall response rate(BOR) of CAR-T cell preparations in CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma[Effectiveness]

    Best overall response rate rate after infusion 1 month and 3 month: proportion of patients who achieve optimal response (CR or PR) with MC-1-50 cell therapy (Assessed by investigators according to the Lugano 2014 criteria)#the minimum value is 0%#maximum value is 100%, and higher scores mean a better outcome.

    Time frame: 3 months

  3. Assessing best complete response rate(CRR) of CAR-T cell preparations in CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma[Effectiveness]

    Complete response rate rate after infusion 1 month and 3 month: proportion of patients who achieve CR with MC-1-50 cell therapy (Assessed by investigators according to the Lugano 2014 criteria)#the minimum value is 0%#maximum value is 100%, and higher scores mean a better outcome.

    Time frame: 3 months

  4. Assessing best partial response rate(PRR) of CAR-T cell preparations in CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma[Effectiveness]

    Partial response rate rate after infusion 1 month and 3 month: proportion of patients who achieve PR with MC-1-50 cell therapy (Assessed by investigators according to the Lugano 2014 criteria)#the minimum value is 0%#maximum value is 100%, and higher scores mean a better outcome.

    Time frame: 3 months

  5. AUCS of MC-1-50 cell preparation [Cell dynamics]

    AUCS is defined as the area under the curve in 90 days

    Time frame: 3 months

  6. CMAX of MC-1-50 cell preparation [Cell dynamics]

    CMAX is defined as the highest concentration of CEA CAR-T cells expanded in peripheral blood

    Time frame: 3 months

  7. TMAX of MC-1-50 cell preparation[Cell dynamics]

    TMAX is defined as the time to reach the highest concentration

    Time frame: 3 months

  8. Pharmacodynamics of MC-1-50 cell preparation[Cell dynamics]

    The clearance degree of CD19-positive B cells in peripheral blood was detected by flow cytometry at the visit points specified in the research protocol

    Time frame: 3 months

  9. To evaluate the immunogenicity positive rate of MC-1-50 cell preparation after infusion

    The anti-CAR antibody was detected by ELISAt the visit points specified in the research protocol

    Time frame: 3 months

Other outcomes

  1. Objective response rate (ORR) of MC-1-50 cell treatment in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma[Effectiveness]

    Objective response rate : The proportion of subjects who achieved CR, PR after CAR-T infusion accounted for all treated subjects (Assessed by investigators according to the Lugano 2014 criteria)#the minimum value is 0%#maximum value is 100%, and higher scores mean a better outcome.

    Time frame: 2 years

  2. Duration of Response (DOR) of MC-1-50 cell treatment in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma[Effectiveness]

    DOR will be assessed from the first assessment of CR/PR to the first assessment of recurrence or progression of the disease or death from any cause

    Time frame: 2 years

  3. Progress-free survival(PFS) of MC-1-50 cell treatment in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma[Effectiveness]

    PFS will be assessed from the first MC-1-50 cell infusion to death from any cause or the first assessment of progression

    Time frame: 2 years

  4. Overall survival(OS)of MC-1-50 cell treatment in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma[Effectiveness]

    OS will be assessed from the first MC-1-50 cell infusion to death from any cause

    Time frame: 2 years

  5. Event-Free survival(EFS) of MC-1-50 cell treatment in patients with CD19-positive relapsed/refractory B-cell non-Hodgkin lymphoma[Effectiveness]

    EFS will be assessed from the first MC-1-50 cell infusion to death from any cause or Disease progression or Treatment failure

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2023; primary completion for Dec 2025, 24 months later.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's planned 24 months is below that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2023
First posted
Dec 22, 2023
StartEst.
Dec 31, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Dec 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06180174
Responsible party
Sponsor
First posted
Dec 22, 2023
Start date
Dec 31, 2023 (estimated)
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 28, 2023

Study contacts

Yuqin Song, M.D
Contact
songyq_vip@163.com
88196118 ext. 010
Yuqin Song, M.D
principal investigator · Peking University Cancer Hospital & Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion